tiprankstipranks
Trending News
More News >
AstraZeneca PLC (GB:AZN)
LSE:AZN
UK Market

AstraZeneca (AZN) Share Forecast & Price Target

Compare
675 Followers
See the Price Targets and Ratings of:

AZN Analyst Ratings

Moderate Buy
15Ratings
Moderate Buy
11 Buy
4 Hold
0 Sell
Based on 15 analysts giving stock ratings to
AstraZeneca
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

13,232.62p
▲(23.67%Upside)
Based on 15 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is 13,232.62p with a high forecast of 16,500.00p and a low forecast of 10,900.00p. The average price target represents a 23.67% change from the last price of 10,700.00p.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10316":"10,316p","16501":"16,501p","11862.25":"11,862.3p","13408.5":"13,408.5p","14954.75":"14,954.8p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">17K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13232.62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">13K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">11K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10316,11862.25,13408.5,14954.75,16501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10574,11029.846153846154,11485.692307692309,11941.538461538461,12397.384615384615,12853.23076923077,13309.076923076924,13764.923076923078,14220.76923076923,14676.615384615385,15132.461538461539,15588.307692307691,16044.153846153848,{"y":16500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10574,10778.50923076923,10983.018461538462,11187.527692307693,11392.036923076923,11596.546153846155,11801.055384615385,12005.564615384616,12210.073846153846,12414.583076923078,12619.092307692308,12823.601538461538,13028.11076923077,{"y":13232.62,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10574,10599.076923076924,10624.153846153846,10649.23076923077,10674.307692307691,10699.384615384615,10724.461538461539,10749.538461538461,10774.615384615385,10799.692307692309,10824.76923076923,10849.846153846154,10874.923076923076,{"y":10900,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11941.55,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12053.23,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12256.99,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13085.44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11630.62,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10863.79,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10402.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10317.74,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11181.17,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11968,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11366,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10608,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10574,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target16,500pAverage Price Target13,233pLowest Price Target10,900p
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on GB:AZN
TipRanks AITipRanks
Not Ranked
TipRanks
12,412p
Buy
16.00%
Upside
Reiterated
06/06/25
AstraZeneca's robust financial performance, coupled with positive earnings call highlights and strategic corporate events, underpin its strong stock score. While technical indicators are neutral, the company's favorable outlook and valuation metrics support a positive investment perspective.
Deutsche Bank  Analyst forecast on GB:AZN
Emmanuel PapadakisDeutsche Bank
Deutsche Bank
11,000p
Hold
2.80%
Upside
Reiterated
06/04/25
Deutsche Bank Reaffirms Their Hold Rating on AstraZeneca (AZN)
UBS
14,200p
Buy
32.71%
Upside
Reiterated
06/03/25
UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)
Barclays Analyst forecast on GB:AZN
Unknown AnalystBarclays
Not Ranked
Barclays
14,000p
Buy
30.84%
Upside
Reiterated
06/03/25
Barclays Sticks to Their Buy Rating for AstraZeneca (AZN)
J.P. Morgan Analyst forecast on GB:AZN
James GordonJ.P. Morgan
J.P. Morgan
14,000p
Buy
30.84%
Upside
Reiterated
06/02/25
AstraZeneca (AZN) Gets a Buy from J.P. Morgan
Bank of America Securities Analyst forecast on GB:AZN
Sachin JainBank of America Securities
Bank of America Securities
14,500p
Buy
35.51%
Upside
Reiterated
06/02/25
AstraZeneca's Promising Clinical Data and Strategic Trials Justify Buy Rating
Goldman Sachs Analyst forecast on GB:AZN
Rajan SharmaGoldman Sachs
Goldman Sachs
14,482p14,524p
Buy
35.74%
Upside
Reiterated
06/02/25
AstraZeneca's Promising Outlook: Buy Rating Backed by Positive DESTINY-Breast09 Trial Results and 35.5% Upside Potential
Guggenheim
11,900p
Buy
11.21%
Upside
Reiterated
05/27/25
Guggenheim Keeps Their Buy Rating on AstraZeneca (AZN)
Bernstein Analyst forecast on GB:AZN
Justin SmithBernstein
Bernstein
16,500p
Buy
54.21%
Upside
Reiterated
05/21/25
Bernstein Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on GB:AZN
Luisa HectorBerenberg Bank
Berenberg Bank
14,000p
Buy
30.84%
Upside
Reiterated
05/16/25
Berenberg Bank Reaffirms Their Buy Rating on AstraZeneca (AZN)
DZ BANK AG Analyst forecast on GB:AZN
Elmar KrausDZ BANK AG
DZ BANK AG
Hold
Reiterated
04/30/25
AstraZeneca (AZN) Gets a Hold from DZ BANK AG
Morgan Stanley Analyst forecast on GB:AZN
Sarita KapilaMorgan Stanley
Morgan Stanley
14,500p13,700p
Buy
28.04%
Upside
Reiterated
04/30/25
AstraZeneca price target lowered to 13,700 GBp at Morgan StanleyAstraZeneca price target lowered to 13,700 GBp at Morgan Stanley
Kepler Capital  Analyst forecast on GB:AZN
David EvansKepler Capital
Kepler Capital
11,300p
Hold
5.61%
Upside
Reiterated
04/29/25
Kepler Capital Remains a Hold on AstraZeneca (AZN)
Jefferies
10,900p
Hold
1.87%
Upside
Reiterated
04/29/25
AstraZeneca (AZN) Receives a Hold from Jefferies
Shore Capital Analyst forecast on GB:AZN
Unknown AnalystShore Capital
Not Ranked
Shore Capital
Buy
Reiterated
04/29/25
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on GB:AZN
TipRanks AITipRanks
Not Ranked
TipRanks
12,412p
Buy
16.00%
Upside
Reiterated
06/06/25
AstraZeneca's robust financial performance, coupled with positive earnings call highlights and strategic corporate events, underpin its strong stock score. While technical indicators are neutral, the company's favorable outlook and valuation metrics support a positive investment perspective.
Deutsche Bank  Analyst forecast on GB:AZN
Emmanuel PapadakisDeutsche Bank
Deutsche Bank
11,000p
Hold
2.80%
Upside
Reiterated
06/04/25
Deutsche Bank Reaffirms Their Hold Rating on AstraZeneca (AZN)
UBS
14,200p
Buy
32.71%
Upside
Reiterated
06/03/25
UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)
Barclays Analyst forecast on GB:AZN
Unknown AnalystBarclays
Not Ranked
Barclays
14,000p
Buy
30.84%
Upside
Reiterated
06/03/25
Barclays Sticks to Their Buy Rating for AstraZeneca (AZN)
J.P. Morgan Analyst forecast on GB:AZN
James GordonJ.P. Morgan
J.P. Morgan
14,000p
Buy
30.84%
Upside
Reiterated
06/02/25
AstraZeneca (AZN) Gets a Buy from J.P. Morgan
Bank of America Securities Analyst forecast on GB:AZN
Sachin JainBank of America Securities
Bank of America Securities
14,500p
Buy
35.51%
Upside
Reiterated
06/02/25
AstraZeneca's Promising Clinical Data and Strategic Trials Justify Buy Rating
Goldman Sachs Analyst forecast on GB:AZN
Rajan SharmaGoldman Sachs
Goldman Sachs
14,482p14,524p
Buy
35.74%
Upside
Reiterated
06/02/25
AstraZeneca's Promising Outlook: Buy Rating Backed by Positive DESTINY-Breast09 Trial Results and 35.5% Upside Potential
Guggenheim
11,900p
Buy
11.21%
Upside
Reiterated
05/27/25
Guggenheim Keeps Their Buy Rating on AstraZeneca (AZN)
Bernstein Analyst forecast on GB:AZN
Justin SmithBernstein
Bernstein
16,500p
Buy
54.21%
Upside
Reiterated
05/21/25
Bernstein Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on GB:AZN
Luisa HectorBerenberg Bank
Berenberg Bank
14,000p
Buy
30.84%
Upside
Reiterated
05/16/25
Berenberg Bank Reaffirms Their Buy Rating on AstraZeneca (AZN)
DZ BANK AG Analyst forecast on GB:AZN
Elmar KrausDZ BANK AG
DZ BANK AG
Hold
Reiterated
04/30/25
AstraZeneca (AZN) Gets a Hold from DZ BANK AG
Morgan Stanley Analyst forecast on GB:AZN
Sarita KapilaMorgan Stanley
Morgan Stanley
14,500p13,700p
Buy
28.04%
Upside
Reiterated
04/30/25
AstraZeneca price target lowered to 13,700 GBp at Morgan StanleyAstraZeneca price target lowered to 13,700 GBp at Morgan Stanley
Kepler Capital  Analyst forecast on GB:AZN
David EvansKepler Capital
Kepler Capital
11,300p
Hold
5.61%
Upside
Reiterated
04/29/25
Kepler Capital Remains a Hold on AstraZeneca (AZN)
Jefferies
10,900p
Hold
1.87%
Upside
Reiterated
04/29/25
AstraZeneca (AZN) Receives a Hold from Jefferies
Shore Capital Analyst forecast on GB:AZN
Unknown AnalystShore Capital
Not Ranked
Shore Capital
Buy
Reiterated
04/29/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

1 Month
xxx
Success Rate
17/32 ratings generated profit
53%
Average Return
+0.09%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.13% of your transactions generating a profit, with an average return of +0.09% per trade.
3 Months
xxx
Success Rate
24/42 ratings generated profit
57%
Average Return
+1.92%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +1.92% per trade.
1 Year
Success Rate
27/33 ratings generated profit
82%
Average Return
+13.96%
reiterated a buy rating 4 days ago
Copying Matthew Weston's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +13.96% per trade.
2 Years
xxx
Success Rate
27/33 ratings generated profit
82%
Average Return
+22.41%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 81.82% of your transactions generating a profit, with an average return of +22.41% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
0
0
0
2
2
Buy
31
43
51
42
32
Hold
12
10
12
8
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
43
53
63
52
42
In the current month, AZN has received 34 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. AZN average Analyst price target in the past 3 months is 13,232.62.
Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

Next quarter’s earnings estimate for AZN is 1.62p with a range of 1.35p to 1.85p. The previous quarter’s EPS was 1.84p. AZN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year AZN has Outperformed its overall industry.
Next quarter’s earnings estimate for AZN is 1.62p with a range of 1.35p to 1.85p. The previous quarter’s EPS was 1.84p. AZN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year AZN has Outperformed its overall industry.

AZN Sales Forecast

Next quarter’s sales forecast for AZN is 10.37B with a range of 10.09B to 10.93B. The previous quarter’s sales results were 10.79B. AZN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year AZN has Outperformed its overall industry.
Next quarter’s sales forecast for AZN is 10.37B with a range of 10.09B to 10.93B. The previous quarter’s sales results were 10.79B. AZN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year AZN has Outperformed its overall industry.

AZN Stock Forecast FAQ

What is GB:AZN’s average 12-month price target, according to analysts?
Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 13,232.62.
    What is GB:AZN’s upside potential, based on the analysts’ average price target?
    AstraZeneca PLC has 23.67% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AstraZeneca PLC a Buy, Sell or Hold?
          AstraZeneca PLC has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 4 hold ratings and 0 sell ratings.
            What is AstraZeneca PLC’s share price target?
            The average share price target for AstraZeneca PLC is 13,232.62. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is 16,500.00p ,and the lowest forecast is 10,900.00p. The average share price target represents 23.67% Increase from the current price of 10,700p.
              What do analysts say about AstraZeneca PLC?
              AstraZeneca PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
                How can I buy shares of AstraZeneca PLC?
                To buy shares of GB:AZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis